(NASDAQ: KMDA) Kamada's forecast annual revenue growth rate of 7.14% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 285.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59%.
Kamada's revenue in 2025 is $174,787,000.On average, 6 Wall Street analysts forecast KMDA's revenue for 2025 to be $10,596,452,062, with the lowest KMDA revenue forecast at $10,104,208,997, and the highest KMDA revenue forecast at $10,985,761,122. On average, 5 Wall Street analysts forecast KMDA's revenue for 2026 to be $11,668,345,840, with the lowest KMDA revenue forecast at $11,070,868,568, and the highest KMDA revenue forecast at $12,199,692,327.
In 2027, KMDA is forecast to generate $12,360,706,413 in revenue, with the lowest revenue forecast at $11,646,493,928 and the highest revenue forecast at $12,995,561,956.